Japanese
English
Home
About Us
Our Mission
Leadership
Message from CEO
Corporate Information
Access
Our Science
PRIME Technology
Application of Our Technology
Pipelines
Our Partners
Careers
Contact Us
Contact Us
Create the Future to Overcome Cancer
News
2022/11/25
Interim results of Phase 1 clinical trial evaluating the ‘PRIME' CAR-T cell therapy TAK-102 (NIB102) expressing IL-7/CCL19 in patients with GPC3 positive solid tumors were presented at the 37th Annual Meeting of SITC
2022/09/12
On September 11, 2022, our president, Koji Tamada, appeared on NHK Science Zero, ”Challenge cancer with immune-therapy ! CAR-T Cell Therapy”
2022/08/31
Implementation of a Third-Party Allocation of New Shares
2022/08/22
Chugai and Noile-Immune Biotech Enters into a License Agreement for Noile-Immune’s PRIME CAR-T Technology
2022/06/17
Noile Immune Biotech was introduced as one of Japan's five hottest biotech companies in healthcare at the Labiotech.eu website.
Please refer our website about the details of our pipelines mentioned in the article.
Details
